ArticleNature communications2021
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Testicular aggressive B-cell lymphoma with plasmablastic morphology harboring concurrent IGH::MYC and IGH::BCL2 rearrangements.Journal of hematopathology · 2026Article
- Joint Assessment of CD38, CD138, and Immunoglobulin Light Chains Supports the Differential Diagnosis Between Classical Hodgkin Lymphoma and Plasmablastic Lymphoma.International journal of laboratory hematology · 2026Article
- When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?Hematology. American Society of Hematology. Education Program · 2025Review
- What to know about rare B-cell malignancies in 2025.Hematology. American Society of Hematology. Education Program · 2025Review
- CD20-Negative Large B-Cell Lymphomas: The Diagnostic Challenge of Tumors with Downregulation of Mature B-Cell Marker Expression.International journal of molecular sciences · 2025Review
- The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential.Blood advances · 2025Article
- Review
- [Chinese expert consensus on the diagnosis and treatment of plasmablastic lymphoma (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Diagnostic approach to leukemia cutis : A differential diagnostic step-by-step algorithm.American journal of clinical pathology · 2025Review
- Transformation of t(14;18)-negative follicular lymphoma to plasmablastic lymphoma: a case report with analysis of genetic evolution.Diagnostic pathology · 2024Article
- Plasmablastic Lymphoma. A State-of-the-Art Review: Part 1-Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Prognostic Factors, and Special Populations.Mediterranean journal of hematology and infectious diseases · 2024Review
- Plasmablastic lymphoma: current knowledge and future directions.Frontiers in immunology · 2024Review
- Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms.Leukemia · 2023Article
- Review
- Article
- Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer.International journal of molecular sciences · 2023Article
- Transformed Plasmablastic Lymphoma Presenting With Marked Lymphocytosis and Spontaneous Tumor Lysis Syndrome.Journal of hematology · 2023Article
- HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report.Journal of cellular and molecular medicine · 2023Article
- Primary refractory plasmablastic lymphoma: A precision oncology approach.Frontiers in oncology · 2023Article
- Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma.The American journal of surgical pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 19 institutions in 4 countries.
Fabian FrontzekDepartment of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.ORCID 0000-0003-1705-3638
Annette M StaigerDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tübingen, Germany.ORCID 0000-0002-5896-3200
Myroslav ZapukhlyakDepartment of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
Wendan XuDepartment of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
Irina BonzheimInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen-Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
Vanessa BorgmannInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen-Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
Philip SanderInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen-Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
Maria Joao BaptistaDepartment of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain.ORCID 0000-0003-3471-2535
Jan-Niklas HemingDepartment of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
Philipp BerningDepartment of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
Ramona WullenkordDepartment of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
Tabea ErdmannDepartment of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
Mathias LutzDepartment of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.ORCID 0000-0002-2572-5687
Pia VerattiDepartment of Psychiatry and Psychotherapy, University Hospital Freiburg, Freiburg, Germany.
Sophia EhrenfeldDepartment of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Kirsty WienandDepartment of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0001-9548-4420
Heike HornDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tübingen, Germany.
John R GoodladDepartment of Pathology, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Matthew R WilsonDepartment of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.ORCID 0000-0001-5423-3270
Ioannis AnagnostopoulosInstitute of Pathology, University of Würzburg, Würzburg, Germany.
Mario LampingCharité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Eva Gonzalez-BarcaDepartment of Hematology. ICO-Hospital Duran i Reynals, Universitat de Barcelona, L'Hospitalet de Llobregat, Llobregat, Spain.ORCID 0000-0002-1323-1508
Fina ClimentDepartment of Pathology. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Llobregat, Spain.
Antonio SalarDepartment of Hematology, Hospital del Mar, Barcelona, Spain.ORCID 0000-0002-4652-4825
Josep CastellviDepartment of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0001-5745-9996
Pau AbrisquetaDepartment of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Javier MenarguezDepartment of Pathology, Hospital Gregorio Marañón, Madrid, Spain.
Teresa AldamizDepartment of Infectious Diseases, Hospital Gregorio Marañón, Madrid, Spain.
Julia RichterDivision of Hematophathology, Christian-Albrechts-University, Kiel, Germany.ORCID 0000-0002-9543-4084
Wolfram KlapperDivision of Hematophathology, Christian-Albrechts-University, Kiel, Germany.ORCID 0000-0001-7208-4117
Alexandar TzankovInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.ORCID 0000-0002-1100-3819
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Andreas RosenwaldInstitute of Pathology, University of Würzburg, Würzburg, Germany.
José Luis MateDepartment of Pathology, Hospital Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, Badalona, Spain.
Gustavo TapiaDepartment of Pathology, Hospital Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, Badalona, Spain.
Peter LenzDepartment of Physics, University of Marburg, Marburg, Germany.
Cornelius MiethingDepartment of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0003-4699-3805
Wolfgang HartmannDivision of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.ORCID 0000-0002-7609-5021
Björn ChapuyDepartment of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
Falko FendInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen-Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-5496-293X
German OttDepartment of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany.
José-Tomas NavarroDepartment of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain.ORCID 0000-0001-9101-6013
Michael Grau *Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
Georg Lenz *Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany. Georg.Lenz@ukmuenster.de.ORCID 0000-0002-4728-1693
University Hospital Münster · DEUniversitat Autònoma de Barcelona · ESUniversity of Tübingen · DERobert Bosch Hospital · DEChristian-Albrechts-Universität zu Kiel · DEHospital General Universitario Gregorio Marañón · ESUniversitätsmedizin Göttingen · DEUniversity Hospital of Basel · CHUniversity of Freiburg · DEUniversity of Würzburg · DEVall d'Hebron Hospital Universitari · ESBeatson West of Scotland Cancer Centre · GBBellvitge University Hospital · ESDuran i Reynals Hospital · ESHospital Del Mar · ESHumboldt-Universität zu Berlin · DEPhilipps University of Marburg · DEQueen Elizabeth University Hospital · GBUniversity Medical Center Freiburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmablastic lymphoma (PBL) represents a rare and aggressive lymphoma subtype frequently associated with immunosuppression. Clinically, patients with PBL are characterized by poor outcome. The current understanding of the molecular pathogenesis is limited. A hallmark of PBL represents its plasmacytic differentiation with loss of B-cell markers and, in 60% of cases, its association with Epstein-Barr virus (EBV). Roughly 50% of PBLs harbor a MYC translocation. Here, we provide a comprehensive integrated genomic analysis using whole exome sequencing (WES) and genome-wide copy number determination in a large cohort of 96 primary PBL samples. We identify alterations activating the RAS-RAF, JAK-STAT, and NOTCH pathways as well as frequent high-level amplifications in MCL1 and IRF4. The functional impact of these alterations is assessed using an unbiased shRNA screen in a PBL model. These analyses identify the IRF4 and JAK-STAT pathways as promising molecular targets to improve outcome of PBL patients.
Indexed as
AdolescentAdultAgedAged, 80 and overCohort StudiesExome SequencingFemaleGene AmplificationGene DosageGene Expression ProfilingHumansInterferon Regulatory Factor-4Interferon Regulatory FactorsJanus KinasesMaleMiddle AgedInterferon Regulatory Factor-4Interferon Regulatory FactorsJanus KinasesSTAT Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.